AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23324524 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenylbutyrate (NaPBA)
Number of subjects: 15
Study 23325011 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0
Study 23325011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23325012 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly pegylated epoetin Beta
Number of subjects: 0
Study 23325012 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa every two weeks
Number of subjects: 0
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed media recruitment approach
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: General media recruitment approach
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborations with support groups/interest groups
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Local free advertising resources (Craigslist and Backpage)
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician outreach
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based approaches
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from study participants and screenees
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall multipronged recruitment approach
Number of subjects: 50
Study 23325028 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment model
Number of subjects: 50
Study 23325073 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD with NGT
Number of subjects: 31
Study 23325073 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD with IGT
Number of subjects: 31
Study 23325073 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 31
Study 23325073 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD groups (NGT and IGT)
Number of subjects: 31
Study 23325902 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (oral), starting at 3 mg/m2 per day, titrated to achieve trough concentrations of 5-15 ng/mL.
Number of subjects: 28
Study 23325915 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 2% nonoxynol-9 (N-9) gel
Number of subjects: 10
Study 23325915 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of Normosol-R fluid alone (negative control)
Number of subjects: 10
Study 23325915 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of Normosol-R with coital simulation and sigmoidoscopic biopsy (CS + BX)
Number of subjects: 10
Study 23325920 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine from cooked white rice (CWR) at doses of 10, 15, and 19 mg·kg(-1)·d(-1)
Number of subjects: 5
Study 23325920 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine from oven-browned cooked rice at a dose of 19 mg·kg(-1)·d(-1)
Number of subjects: 5
Study 23325920 — intervention group
Group type: COMPARATOR
Intervention: Reference protein (crystalline AA mixture patterned after egg protein)
Number of subjects: 5
Study 23326928 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily insulin detemir
Number of subjects: 1671
Study 23327295 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis (1 mg/8 h)
Number of subjects: 177
Study 23327629 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 18630
Study 23327629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18630
Study 23328269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation maintenance pemetrexed therapy plus best supportive care (BSC)
Number of subjects: 0
Study 23328269 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 0
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical side sensory dysfunction
Number of subjects: 14
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sensory mapping on day 1
Number of subjects: 14
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sensory mapping on day 2
Number of subjects: 14
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of areas on surgical vs nonsurgical side
Number of subjects: 14
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest assessments
Number of subjects: 14
Study 23328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mirror pain
Number of subjects: 14
Study 23329066 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4877 25 mg administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal
Number of subjects: 39
Study 23329066 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4877 25 mg
Number of subjects: 39
Study 23329066 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4877 Cmax on days 1 and 8
Number of subjects: 39
Study 23329150 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vitamin D levels
Number of subjects: 110
Study 23329150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D levels
Number of subjects: 110
Study 23329150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild renal insufficiency with low vitamin D levels
Number of subjects: 110
Study 23331449 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed intervention
Number of subjects: 1000
Study 23331449 — intervention group
Group type: COMPARATOR
Intervention: Enhanced intervention (physician plus patient activation)
Number of subjects: 1000
Study 23331449 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 1000
Study 23331498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 12
Study 23331498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23331739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment once daily for 12 weeks
Number of subjects: 20
Study 23331739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment continued in open label extension for relapsing patients
Number of subjects: 20
Study 23331739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment for perineal disease
Number of subjects: 20
Study 23331739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment overall safety
Number of subjects: 20
Study 23332165 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting absorbable metal scaffold (DREAMS)
Number of subjects: 46
Study 23332982 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT endograft
Number of subjects: 60
Study 23333188 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ECV by cardiac CT
Number of subjects: 24
Study 23333219 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α antagonists (infliximab, etanercept, adalimumab)
Number of subjects: 34
Study 23335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg QD
Number of subjects: 46
Study 23335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 100 mg QD
Number of subjects: 46
Study 23335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 150 mg QD
Number of subjects: 46
Study 23335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 200 mg QD
Number of subjects: 46
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation group null
Number of subjects: 153
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation group C
Number of subjects: 153
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation groups with more severe genotypes
Number of subjects: 153
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation groups
Number of subjects: 153
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic CAH and women with nonclassic CAH
Number of subjects: 153
Study 23337727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with CAH
Number of subjects: 153
Study 23338490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB)
Number of subjects: 57
Study 23338490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 57
Study 23338490 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 57
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartet LV lead pacing from 10 vectors
Number of subjects: 170
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from additional LV lead pacing vectors
Number of subjects: 170
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogramming pacing output
Number of subjects: 170
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogramming to pace from additional vectors and reprogramming pacing output
Number of subjects: 170
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogramming to pace from additional vectors alone
Number of subjects: 170
Study 23339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of Quartet LV lead
Number of subjects: 170
Study 23339757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multi-center intervention study targeting family diabetes management)
Number of subjects: 340
Study 23339757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 340
Study 23340184 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible cerebral NIRS oximetry with pre-specified treatment guidelines
Number of subjects: 10
Study 23340184 — intervention group
Group type: COMPARATOR
Intervention: Standard care with blinded NIRS-monitoring
Number of subjects: 10
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct patient contact
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect patient care
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with other staff
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of work
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal time
Number of subjects: 9
Study 23340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Other activities
Number of subjects: 9
Study 23340188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 390
Study 23340188 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 390
Study 23340188 — intervention group
Group type: COMPARATOR
Intervention: Complicated appendicitis
Number of subjects: 390
Study 23340188 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative length of stay (LOS)
Number of subjects: 390
Study 23340188 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 390
Study 23340188 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission
Number of subjects: 390
Study 23340188 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-satisfactory outcomes
Number of subjects: 390
Study 23340271 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 647
Study 23340271 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapies (CMTs)
Number of subjects: 647
Study 23340531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100 - 250 mg bid)
Number of subjects: 4
Study 23340882 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI-CLI group (111 patients with CLI)
Number of subjects: 764
Study 23340882 — intervention group
Group type: COMPARATOR
Intervention: PCI-only group (653 patients without CLI)
Number of subjects: 764
Study 23341491 — intervention group
Group type: EXPERIMENTAL
Intervention: iv pulsatile GnRH (75 ng/kg per bolus)
Number of subjects: 37
Study 23341526 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus whole-brain radiation therapy (WBRT)
Number of subjects: 40
Study 23341526 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus WBRT
Number of subjects: 40
Study 23342272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 14
Study 23343427 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox®) 400 mg once daily for a mean duration of 6.4 ± 1.9 days
Number of subjects: 2536
Study 23343427 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox®)
Number of subjects: 2536
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving neuromuscular block reversal agents (66.6% of patients; neostigmine in 97%)
Number of subjects: 350
Study 23344123 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving neuromuscular block reversal agents
Number of subjects: 350
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving propofol
Number of subjects: 350
Study 23344123 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving sevoflurane
Number of subjects: 350
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving cisatracurium
Number of subjects: 350
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving vecuronium
Number of subjects: 350
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving atracurium
Number of subjects: 350
Study 23344123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving rocuronium
Number of subjects: 350
Study 23344286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (dosage and duration not specified)
Number of subjects: 0
Study 23344397 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon tamponade combined with medical management
Number of subjects: 1
Study 23344397 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 1
Study 23344409 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for malignancy and consideration of hysterectomy after childbearing is completed.
Number of subjects: 1
Study 23345012 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive cognitive function (ECF)
Number of subjects: 1005
Study 23345012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and exercising with parents
Number of subjects: 1005
Study 23348202 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fluid (15 ml kg(-1) in 30 min)
Number of subjects: 30
Study 23348202 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV
Number of subjects: 30
Study 23348202 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 30
Study 23348202 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 30
Study 23348202 — intervention group
Group type: EXPERIMENTAL
Intervention: Eadyn
Number of subjects: 30
Study 23348203 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteal sciatic nerve block with 20 ml of ropivacaine 4.75 mg ml(-1)
Number of subjects: 72
Study 23348203 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic patients)
Number of subjects: 72
Study 23348658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) providing 3.3-4.2 MJ/day to replace all meals
Number of subjects: 938
Study 23348820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0
Study 23348820 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 23348820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 0
Study 23348820 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0
Study 23348820 — intervention group
Group type: COMPARATOR
Intervention: Clinical Depression
Number of subjects: 0
Study 23348820 — intervention group
Group type: COMPARATOR
Intervention: Sleep Apnea
Number of subjects: 0
Study 23348820 — intervention group
Group type: COMPARATOR
Intervention: Thyroid Disease
Number of subjects: 0
Study 23348979 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOCHA score (simplified score for difficult intubation)
Number of subjects: 1000
Study 23348979 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOCHA score (validation cohort)
Number of subjects: 1000
Study 23348979 — intervention group
Group type: COMPARATOR
Intervention: Difficult intubation
Number of subjects: 1000
Study 23349326 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stromal cells (MSCs) - 1 million cells per kilogram, two intravenous infusions
Number of subjects: 6
Study 23349346 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal fragment of proBNP (Nt-proBNP)
Number of subjects: 361
Study 23349346 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients followed for AS-related events
Number of subjects: 361
Study 23349878 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA vaccine
Number of subjects: 425
Study 23349878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) levels during malaria episode
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 levels during malaria episode
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM-1 levels during malaria episode
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: sE-Selectin levels during malaria episode
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: sTM levels during malaria episode
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UA levels with parasite density in UM
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sICAM-1 levels with UA levels in UM
Number of subjects: 555
Study 23349902 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sTM levels with UA levels in UM
Number of subjects: 555
Study 23350893 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 32871
Study 23350893 — intervention group
Group type: COMPARATOR
Intervention: Low education category
Number of subjects: 32871
Study 23350893 — intervention group
Group type: COMPARATOR
Intervention: Higher education category
Number of subjects: 32871
Study 23351121 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 0
Study 23351121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and genetic factors
Number of subjects: 0
Study 23351121 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic, environmental, and clinical risk factors
Number of subjects: 0
Study 23351590 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (single dose)
Number of subjects: 12
Study 23351618 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch) for 30 minutes
Number of subjects: 482
Study 23351618 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch) for 60 minutes
Number of subjects: 482
Study 23351618 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration control patch (capsaicin 0.04% w/w)
Number of subjects: 482
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 311
Study 23352199 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 311
Study 23352199 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 311
Study 23352199 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 311
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of valproate
Number of subjects: 311
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional folate
Number of subjects: 311
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 311
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine group
Number of subjects: 311
Study 23352199 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate group
Number of subjects: 311
Study 23352429 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (120 μg doses at 0, 1, and 6 months)
Number of subjects: 60
Study 23352786 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum Lumen Area (MLA) <3.07 mm²
Number of subjects: 350
Study 23352786 — intervention group
Group type: EXPERIMENTAL
Intervention: MLA <2.4 mm²
Number of subjects: 350
Study 23352786 — intervention group
Group type: EXPERIMENTAL
Intervention: MLA <2.7 mm²
Number of subjects: 350
Study 23352786 — intervention group
Group type: EXPERIMENTAL
Intervention: MLA <3.6 mm²
Number of subjects: 350
Study 23352786 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 350
Study 23353804 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician assessment of oral changes according to NIH criteria
Number of subjects: 458
Study 23353804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptom and quality-of-life measures
Number of subjects: 458
Study 23353804 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician and patient assessments of oral changes
Number of subjects: 458
Study 23353804 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement changes predictive of perceived change
Number of subjects: 458
Study 23354509 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful CPAP therapy (n = 16)
Number of subjects: 50
Study 23354509 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful CPAP therapy (n = 8)
Number of subjects: 50
Study 23354509 — intervention group
Group type: COMPARATOR
Intervention: No OSA (n = 16)
Number of subjects: 50
Study 23354509 — intervention group
Group type: EXPERIMENTAL
Intervention: HFC ≥ 50 %
Number of subjects: 50
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo sentinel lymph node procedure with isosulfan blue 1 %
Number of subjects: 174